Primary mucinous cystadenocarcinoma of the breast commonly harbours TP53 mutations and PI3K/AKT pathway alterations
- 24 November 2025
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (6) , 1235-1246
Abstract
Primary mucinous cystadenocarcinoma (MCA) of the breast is an invasive breast carcinoma characterized by cystic structures lined by tall columnar cells with abundant intracytoplasmic mucin, resembling pancreatobiliary or ovarian mucinous cystadenocarcinoma. Fewer than 50 cases have been reported worldwide so far. In this series, we describe the clinical, morphologic, immunohistochemical, and molecular features of 5 cases of breast MCA. The median age of the patients was 54 years (range: 53 to 64 years) and invasive size was 2 mm to 30 mm (our study reported the smallest invasive size to date in case 5). DCIS was present in 4 of 5 cases. Despite the prevailing view that breast MCA may be indolent, our cases exhibit robust growth, characterized by a relatively high Ki67 index, brisk mitosis, and 1 case of micrometastasis of axillary lymph node micrometastasis. Moreover, we conducted large panel sequencing on 4 cases, and emphasize their molecular essence; that is, breast MCA exhibits a high frequency of TP53 mutations and PI3K/AKT pathway alterations. A review of the literature on previous and current genomic profiles indicates that MCAs are similar to triple-negative breast cancer (TNBC). In our opinion, patients with breast MCA should receive precise clinical treatment similarly to invasive breast carcinoma of no special type, with careful consideration of tumor grade, stage, immunophenotype, and genomic profile, and we believe that PI3K-targeted therapies may play a valuable role in treating this rare tumor.Keywords
This publication has 36 references indexed in Scilit:
- HER2‐positive mucinous cystadenocarcinoma of the breast coexisting with invasive lobular carcinoma: A case report and review of the literatureDiagnostic Cytopathology, 2024
- TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancerLaboratory Investigation, 2021
- Breast Metastases Secondary to Primary Pancreatic Mucinous CystadenocarcinomaPancreas, 2021
- The molecular origin and taxonomy of mucinous ovarian carcinomaNature Communications, 2019
- Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2019
- Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment StrategiesCancer Cell, 2019
- Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patientsNature Communications, 2018
- Mucinous cystadenocarcinoma of the breast with amplification of the HER2-gene confirmed by FISH: The first case reportedHuman Pathology, 2010
- Mucinous Cystadenocarcinoma of the BreastAmerican Journal of Surgical Pathology, 1998
- Metastasis of Breast Carcinoma to a Primary Mucinous Cystadenocarcinoma of the OvaryGynecologic Oncology, 1994